Načítá se...
The clinical utility of aflibercept for diabetic macular edema
The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest anti-VEGF drug, aflibercept, has recently been approved by the United States Food and Drug Administrat...
Uloženo v:
| Vydáno v: | Diabetes Metab Syndr Obes |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4583120/ https://ncbi.nlm.nih.gov/pubmed/26425104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S72792 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|